{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3182"}]}],"title":"30 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2756"}]}],"title":"48 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}],"title":"Other"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"5986"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"All cycles from patients in the evaluable sample","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Dose (All Cycles)","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}